You are here

Final decisions and reasons for NCEs, medicines and chemicals, November 2018

Scheduling medicines and poisons

26 April 2019

These Secretary's final decisions and reasons relate to:

  • scheduling proposals initially referred to the November 2018 meeting of the Advisory Committee on Medicines Scheduling (ACMS #25);
  • scheduling proposals initially referred to the November 2018 meeting of the Joint meeting of the Advisory Committees on Chemicals and Medicines Scheduling (ACCS-ACMS #20); and
  • scheduling proposals initially referred to the November 2018 meeting of the Advisory Committee on Chemicals Scheduling (ACCS #23).

Final decisions and reasons for NCEs, medicines and chemicals, November 2018

How to access a pdf or Word document

We aim to provide documents in an accessible format. If you're having problems using this document, please contact Medicines Scheduling or Chemicals Scheduling.

Contents

  • Part A - Final decisions on matters referred to an expert advisory committee (November 2018)
    • 1. Advisory Committee on Medicines Scheduling (ACMS #25)
      • 1.1. Nabiximols
      • 1.2. Racetams
    • 2. Joint meeting of the Advisory Committee on Chemicals and Medicines Scheduling (ACCS-ACMS #20)
      • 2.1. Salts of boric acid
      • 2.2. Naphthalene
    • 3. Advisory Committee on Chemicals Scheduling (ACCS #23)
      • 3.1. 2-chloro-p-phenylenediamine/2-chloro-p-phenylenediamine sulfate
  • Part B - Final decisions on matters not referred to an expert advisory committee
    • 4. New Chemical Entities - medicines for human therapeutic use
      • 4.1. Galcanezumab
      • 4.2. Doravirine
      • 4.3. Abemaciclib
      • 4.4. Plitidepsin
      • 4.5. Isavuconazole
      • 4.6. Semaglutide
      • 4.7. Cenegermin